LogicBio Therapeutics, Inc. Quarterly Debt-to-equity in % from Q2 2020 to Q3 2022

Taxonomy & unit: ratio: %
Description: Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary: LogicBio Therapeutics, Inc. quarterly Debt-to-equity history and growth rate from Q2 2020 to Q3 2022.
LogicBio Therapeutics, Inc. Debt-to-equity for the quarter ending September 30, 2022 was 117 %, a 131% increase year-over-year.

Debt-to-equity, Quarterly (%)

Debt-to-equity, YoY Quarterly Growth (%)

Period	Value	YoY Chg	Change %	Date
Q3 2022	117	+66.6	+131%	Sep 30, 2022
Q2 2022	99.7	+49.6	+99.2%	Jun 30, 2022
Q1 2022	87.3	+40.6	+86.8%	Mar 31, 2022
Q4 2021	67.8	+17.7	+35.2%	Dec 31, 2021
Q3 2021	50.9	-2.19	-4.13%	Sep 30, 2021
Q2 2021	50.1	+11	+28.1%	Jun 30, 2021
Q1 2021	46.7			Mar 31, 2021
Q4 2020	50.1			Dec 31, 2020
Q3 2020	53.1			Sep 30, 2020
Q2 2020	39.1			Jun 30, 2020

* An asterisk sign (*) next to the value indicates that the value is likely invalid.